{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:14:55Z","timestamp":1771841695105,"version":"3.50.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T00:00:00Z","timestamp":1568851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["AN 2015\/1080"],"award-info":[{"award-number":["AN 2015\/1080"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 2015\/385"],"award-info":[{"award-number":["CAN 2015\/385"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00923","type":"journal-article","created":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T04:35:30Z","timestamp":1568867730000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer Cells"],"prefix":"10.3389","volume":"9","author":[{"given":"Anja Charlotte Lundgren","family":"Mortensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Spiegelberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher John","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Philip","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marika","family":"Nestor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.radonc.2015.04.018","article-title":"The optimal utilization proportion of external beam radiotherapy in European countries: an ESTRO-HERO analysis","volume":"116","author":"Borras","year":"2015","journal-title":"Radiother Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.urology.2013.03.043","article-title":"Developments in external beam radiotherapy for prostate cancer","volume":"82","author":"Lumen","year":"2013","journal-title":"Urology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/antiox5030022","article-title":"Protection against Radiotherapy-Induced Toxicity","volume":"5","author":"Hall","year":"2016","journal-title":"Antioxid Basel Switz"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.ijrobp.2006.10.024","article-title":"Optimizing 4D cone-beam CT acquisition protocol for external beam radiotherapy","volume":"15","author":"Li","year":"2007","journal-title":"Int J Radiat Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0360-3016(77)90089-X","article-title":"Optimization of external beam radiation therapy","volume":"2","author":"McDonald","year":"1977","journal-title":"Int J Radiat Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/cpf.12411","article-title":"18F-FDG PET\/CT for planning external beam radiotherapy alters therapy in 11% of 581 patients","volume":"38","author":"Birk Christensen","year":"2018","journal-title":"Clin Physiol Funct Imaging"},{"key":"B8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.radonc.2018.06.032","article-title":"The impact of margin reduction on outcome and toxicity in head and neck cancer patients treated with image-guided volumetric modulated arc therapy (VMAT)","volume":"130","author":"Navran","year":"2019","journal-title":"Radiother Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.oraloncology.2017.12.004","article-title":"Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study)","volume":"77","author":"Au","year":"2018","journal-title":"Oral Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"11589","DOI":"10.1007\/s13277-016-5117-8","article-title":"Emerging targets for radioprotection and radiosensitization in radiotherapy","volume":"37","author":"Kumar","year":"2016","journal-title":"Tumour Biol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.bbrc.2016.07.062","article-title":"Radiosensitization by PARP inhibition to proton beam irradiation in cancer cells","volume":"478","author":"Hirai","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"B12","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/1759-7714.12332","article-title":"Rapamycin-induced autophagy sensitizes A549 cells to radiation associated with DNA damage repair inhibition","volume":"7","author":"Li","year":"2016","journal-title":"Thorac Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3978\/j.issn.2218-676X.2013.09.01","article-title":"Role of p53 in regulating tissue response to radiation by mechanisms independent of apoptosis","volume":"2","author":"Lee","year":"2013","journal-title":"Transl Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4161\/trns.21297","article-title":"How p53 wields the scales of fate: arrest or death?","volume":"3","author":"Goh","year":"2012","journal-title":"Transcription"},{"key":"B15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/09553000802662595","article-title":"The role of apoptosis in radiation oncology","volume":"85","author":"Meyn","year":"2009","journal-title":"Int J Radiat Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00204-015-1459-z","article-title":"The role of DNA damage responses in p53 biology","volume":"89","author":"Speidel","year":"2015","journal-title":"Arch Toxicol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"22666","DOI":"10.18632\/oncotarget.4433","article-title":"The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer","volume":"6","author":"Deben","year":"2015","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1038\/onc.2009.46","article-title":"Noxa: at the tip of the balance between life and death","volume":"27","author":"Ploner","year":"2009","journal-title":"Oncogene"},{"key":"B19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2174\/138920209787581280","article-title":"MDM4 (MDMX) and its transcript variants","volume":"10","author":"Mancini","year":"2009","journal-title":"Curr Genomics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/abbs\/gmt144","article-title":"Tumor suppressor p53 and its gain-of-function mutants in cancer","volume":"46","author":"Liu","year":"2014","journal-title":"Acta Biochim Biophys Sin"},{"key":"B21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrd4236","article-title":"Drugging the p53 pathway: understanding the route to clinical efficacy","volume":"13","author":"Hoe","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"B22","doi-asserted-by":"publisher","first-page":"12951","DOI":"10.18632\/oncotarget.7339","article-title":"Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients","volume":"7","author":"Trino","year":"2016","journal-title":"Oncotarget"},{"key":"B23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fonc.2016.00007","article-title":"Clinical overview of MDM2\/X-targeted therapies","volume":"6","author":"Burgess","year":"2016","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-017-0500-5","article-title":"MDM2\/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer","volume":"10","author":"Tisato","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1021\/cb3005148","article-title":"Stapled peptides with improved potency and specificity that activate p53","volume":"8","author":"Brown","year":"2013","journal-title":"ACS Chem Biol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"32232","DOI":"10.18632\/oncotarget.8572","article-title":"Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides","volume":"7","author":"Wei","year":"2016","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e81068","DOI":"10.1371\/journal.pone.0081068","article-title":"Inhibition of nutlin-resistant HDM2 mutants by stapled peptides","volume":"8","author":"Wei","year":"2013","journal-title":"PLoS ONE"},{"key":"B28","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1158\/0008-5472.CAN-18-0440","article-title":"The MDM2\/MDMX-p53 antagonist PM2 radiosensitizes wild-type p53 tumors","volume":"78","author":"Spiegelberg","year":"2018","journal-title":"Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5455\/jice.20140123040224","article-title":"Cytotoxicity enhancement in MDA-MB-231 cells by the combination treatment of tetrahydropalmatine and berberine derived from Corydalis yanhusuo W. T. Wang","volume":"3","author":"Zhao","year":"2014","journal-title":"J Intercult Ethnopharmacol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nm0302-282","article-title":"Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound","volume":"8","author":"Bykov","year":"2002","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1038\/sj.onc.1205217","article-title":"TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest","volume":"21","author":"Paterson","year":"2002","journal-title":"Oncogene"},{"key":"B32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.radonc.2013.06.035","article-title":"HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1","volume":"108","author":"Busch","year":"2013","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/hed.10274","article-title":"P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines","volume":"25","author":"Bradford","year":"2003","journal-title":"Head Neck"},{"key":"B34","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1073\/pnas.0510146103","article-title":"Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines","volume":"103","author":"Liu","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.canlet.2015.10.034","article-title":"Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer","volume":"370","author":"Shirai","year":"2016","journal-title":"Cancer Lett"},{"key":"B36","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.neo.2016.01.006","article-title":"MDM2 inhibition sensitizes prostate cancer cells to androgen ablation and radiotherapy in a p53-dependent manner","volume":"18","author":"Feng","year":"2016","journal-title":"Neoplasia N Y N"},{"key":"B37","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.biochi.2015.11.008","article-title":"Idaein chloride induced p53 dependent apoptosis in cervical cancer cells through inhibition of viral oncoproteins","volume":"121","author":"Natarajan","year":"2016","journal-title":"Biochimie"},{"key":"B39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3109\/07357907.2014.905585","article-title":"Biological effects of 125I seeds radiation on A549 lung cancer cells: G2\/M arrest and enhanced cell death","volume":"32","author":"Qu","year":"2014","journal-title":"Cancer Invest"},{"key":"B40","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/ng891","article-title":"Suppression of the p53- or pRB-mediated G1 checkpoint is required for E2F-induced S-phase entry","volume":"31","author":"Lomazzi","year":"2002","journal-title":"Nat Genet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.radonc.2011.06.007","article-title":"Radiobiology goes 3D: How ECM and cell morphology impact on cell survival after irradiation","volume":"99","author":"Eke","year":"2011","journal-title":"Radiother Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00923\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T14:09:33Z","timestamp":1568988573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00923\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,19]]},"references-count":42,"alternative-id":["10.3389\/fonc.2019.00923"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00923","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,19]]},"article-number":"923"}}